CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Creatinine and Urea Point of Care Testing for Patients with Suspected Renal Failure: Clinical Utility, Cost-Effectiveness and Guidelines

Last updated: April 20, 2020
Project Number: RB1465-000
Product Line: Rapid Response
Research Type: Device
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical utility of creatinine and urea point of care testing for patients with suspected renal failure?
  2. What is the cost-effectiveness of creatinine and urea point of care testing for patients with suspected renal failure?
  3. What are the evidence-based guidelines regarding the use of creatinine and urea point of care testing in non-emergency department settings?

Key Message

Four non-randomized studies were identified regarding the clinical utility of creatinine and urea point of care testing with suspected renal failure or impairment. One evidence-based guideline was identified regarding the use of creatinine and urea point of care testing in non-emergency department settings. No economic evaluations were identified regarding the cost-effectiveness of creatinine and urea point of care testing for patients with suspected renal failure.